Level of evidence   93044-6

LOINC Code


LOINC code93044-6
nameLevel of evidence
descriptionIn the interpretation of sequence variants, standard terminology is used to describe the level of evidence that supports the association between a particular genetic variant and a particular disorder or disease state. Three example answer lists for levels of evidence are listed below but we recognize that a local terminology may also be used based on other factors such as population, type of data studied, etc. The example answer list associated with this term is that given by the American College of Medical Genetics, but depending on the use case, other lists may be just as appropriate. American College of Medical Genetics [https://www.acmg.net/docs/standards_guidelines_for_the_interpretation_of_sequence_variants.pdf] Very strong evidence pathogenic Strong evidence pathogenic Moderate evidence pathogenic Supporting evidence pathogenic Supporting evidence benign Strong evidence benign Stand-alone evidence pathogenic Stand-alone evidence benign Uncertain significance PharmGKB CPIC Clinical Annotation Levels of Evidence [https://www.pharmgkb.org/page/clinAnnLevels] Level 1A High Level 1B High Level 2a Moderate Level 2b Moderate Level 3 Low Level 4 Preliminary AMP guidelines to be used for Somatic Variant Interpretation/Reporting (list has meaning for Therapeutic, Diagnostic, and Prognostic uses as further described in the reference). [https://jmd.amjpathol.org/article/S1525-1578(16)30223-9/pdf] Tier 1 Level A - (Strong Clinical Significance) FDA-approved therapy and/or included in professional guidelines. Tier 1 Level B - (Strong Clinical Significance) Well-powered studies with consensus from experts in the field. Tier 2 Level C - (Potential Clinical Significance) FDA-approved therapies for different tumor types or investigational therapies, multiple small published studies with some consensus. Tier 2 Level D - (Potential Clinical Significance) Preclinical trials or a few case reports without consensus. Tier 3 - (Unknown Clinical Significance) Not observed at a significant allele frequency in general or specific subpopulation databases or pan-cancer or tumor-specific variant databases, no convincing published evidence of cancer association. Tier 4 - (Benign or Likely Benign) Observed at significant allele frequency in the general or specific subpopulation databases and no existing published evidence of cancer association.
statusACTIVE

Fully-Specified Name

componentLevel of evidence
propertyFind  =  Finding
timePt  =  Point in time:  To identify measures at a point in time. This is a synonym for “spot” or “random” as applied to urine measurements.
systemBld/Tiss
    Bld  =  Whole blood
    Tiss  =  Tissue, unspecified
scaleNom  =  Nominal:  Nominal or categorical responses that do not have a natural ordering. (e.g., names of bacteria, reported as answers, categories of appearance that do not have a natural ordering, such as, yellow, clear, bloody.
method

Additional Names

short nameLevel of evidence

Basic Attributes

classMOLPATH
type1  Laboratory
order vs. observationObservation

Associated Observations

LOINC codes that represent optional associated observation(s) for a clinical observation or laboratory test. A LOINC term may represent a single associated observation or panel containing several associated observations.

History/Usage

first released
last updated2.66
last change typeADD  - added

Related Names

Blood
Finding
Findings
Levels
Levl
LV
LVL
Molecular pathology
MOLPATH
Nominal
Point in time
Random
Tissue
Tissue, unspecified
WB
Whole blood
Whole blood or Tissue

Copyright © 2024 Regenstrief Institute, Inc. All Rights Reserved. To the extent included herein, the LOINC table and LOINC codes are copyright © 1995-2024, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. See https://loinc.org/license for the full LOINC copyright and license.

demo
request yours today
subscribe
start today
newsletter
free subscription

Thank you for choosing Find-A-Code, please Sign In to remove ads.